2022
DOI: 10.3390/ijms23169299
|View full text |Cite
|
Sign up to set email alerts
|

Biomarkers in Neurodegenerative Diseases: Proteomics Spotlight on ALS and Parkinson’s Disease

Abstract: Neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD) are both characterized by pathogenic protein aggregates that correlate with the progressive degeneration of neurons and the loss of behavioral functions. Both diseases lack biomarkers for diagnosis and treatment efficacy. Proteomics is an unbiased quantitative tool capable of the high throughput quantitation of thousands of proteins from minimal sample volumes. We review recent proteomic studies in human tissues… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
12
0

Year Published

2023
2023
2025
2025

Publication Types

Select...
8
1
1

Relationship

0
10

Authors

Journals

citations
Cited by 25 publications
(12 citation statements)
references
References 122 publications
0
12
0
Order By: Relevance
“…The identified peptides in our dataset are only partially new compared to those in previous studies 14,15 . The differences may be due to enhanced sensitivity of the utilized peptide quantification methods or the fact that the biomarker discovery method used in the majority of earlier studies is different from our holistic and nondigestive peptidomics approach.…”
Section: Discussionmentioning
confidence: 66%
“…The identified peptides in our dataset are only partially new compared to those in previous studies 14,15 . The differences may be due to enhanced sensitivity of the utilized peptide quantification methods or the fact that the biomarker discovery method used in the majority of earlier studies is different from our holistic and nondigestive peptidomics approach.…”
Section: Discussionmentioning
confidence: 66%
“…The identified peptides in our dataset are only partially new compared to those in previous studies [ 16 , 17 ]. The differences may be due to enhanced sensitivity of the utilized peptide quantification methods or the fact that the biomarker discovery method used in the majority of earlier studies is different from our holistic and non-digestive peptidomics approach.…”
Section: Discussionmentioning
confidence: 68%
“…Towards this end, we performed discovery-based studies on pre-fractionated CSF from 20 patients with ALS and 20 HC individuals using an 11-plex TMT platform and discovered 53 candidate ALS biomarker proteins (19 candidates with q < 0.05 and 34 candidates with q < 0.1). Among the 53 candidate ALS biomarker proteins, 44 proteins are novel, and 9 proteins were identified previously as being differentially expressed in ALS, and these include neurofilament proteins (NEFL, NEFM, and NEFH), CHIT1, CHI3L1, CHI3L2, APOB, GPNMB, and UCHL1 [20,41,42]. Neurofilament proteins are intermediate filament proteins that are elevated in response to neuronal damage [25,43], while CHIT1, CHI3L1, and CHI3L2 are members of the human chitinase family that are implicated in inflammation [24].…”
Section: Discussionmentioning
confidence: 99%